The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000559314
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
16/04/2026
Date registered
Help: Date registered
1/05/2026
Date last updated
Help: Date last updated
21/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
1/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Tranexamic acid bladder instillation for blood in the urine requiring bladder irrigation: a randomized controlled trial
Scientific title
Use of intravesical tranexamic acid in macroscopic haematuria: A triple blind randomized control trial assessing the impact on duration of bladder irrigation
Additional trial identifiers [1] 316837 0
Nil Known
Universal Trial Number (UTN)
U1111-1337-7161
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Macroscopic Haematuria 341203 0
Condition category
Condition code
Renal and Urogenital 337289 337289 0 0
Other renal and urogenital disorders
Emergency medicine 337290 337290 0 0
Other emergency care

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
1000mg of tranexamic acid (Tranexamic-AFT, AFT Pharmaceuticals) dissolved in 100ml of 0.9% normal saline is instilled into the bladder via the main lumen of an indwelling urinary catheter (3-way IDC, minimum size 20Fr). The catheter is clamped for 15 minutes. After unclamping, the solution is drained and continuous bladder irrigation (CBI) is commenced immediately without delay.

The study drug is prepared by a designated unblinded clinician (Study Clinician 2) in a container labelled only with the participant's study ID, identical in appearance to the placebo. Prior to study drug administration, manual bladder washout is completed until all intravesical clots are removed based on bedside clinical assessment.

Mode of delivery: Intravesical instillation via indwelling urinary catheter in the Emergency Department.
Dose: 1000mg TXA in 100ml 0.9% normal saline.
Duration: Single administration with 15-minute dwell time.
Location: Emergency Department (Wollongong Hospital, Shoalhaven District Memorial Hospital, Shellharbour Hospital, Milton Ulladulla Hospital).

Continuous bladder irrigation will be standardized for the purposes of the trial, and patients included in the study would have normally been treated with CBI if the study was not taking place. CBI is the process of irrigating the bladder with normal saline through a 3-way indwelling urinary catheter. The rate of CBI started at 100 drops/min and then titrated to the colour of the urine output. CBI is ceased when the urine becomes clear. There is not a specific maximum time duration for CBI.
Intervention code [1] 333525 0
Treatment: Drugs
Description of the comparator or control
Brief name: Intravesical saline placebo

100ml of 0.9% normal saline instilled into the bladder via the main lumen of an indwelling urinary catheter (3-way IDC, minimum size 20Fr), with a 15-minute catheter clamp time, followed by immediate drainage and commencement of CBI.

The placebo is prepared by the designated unblinded clinician in a container identical in appearance to the TXA solution, labelled only with the participant's study ID.

Mode of delivery: Intravesical instillation via indwelling urinary catheter in the Emergency Department.
Dose: 100ml of 0.9% normal saline.
Duration: Single administration with 15-minute dwell time.
Location: Emergency Department.
Control group
Placebo

Outcomes
Primary outcome [1] 344886 0
Duration of continuous bladder irrigation (CBI)
Timepoint [1] 344886 0
Measured within 72 hours of cessation of CBI
Secondary outcome [1] 459596 0
Proportion of participants with complication-free CBI success by 72 hours (sustained cessation greater than 24 hour with no CBI restart). This change has occurred prior to any recruitment.
Timepoint [1] 459596 0
72 hours from CBI commencement
Secondary outcome [2] 459597 0
CBI restart within 72 hours after sustained cessation (more than 24 hours), This change has occurred prior to any recruitment.
Timepoint [2] 459597 0
Within 72 hours of sustained CBI cessation
Secondary outcome [3] 459598 0
Time to CBI restart after sustained cessation
Timepoint [3] 459598 0
Within 72 hours of sustained CBI cessation
Secondary outcome [4] 459599 0
Any requirement for additional CBI within 30 days of study drug administration
Timepoint [4] 459599 0
Within 30 days of study drug administration
Secondary outcome [5] 459600 0
Hospital admission rate
Timepoint [5] 459600 0
At hospital discharge
Secondary outcome [6] 459601 0
Emergency department re-presentation within 72 hours post CBI cessation
Timepoint [6] 459601 0
Within 72 hours of CBI cessation
Secondary outcome [7] 459602 0
Duration of indwelling urinary catheter (IDC) placement
Timepoint [7] 459602 0
From IDC insertion to removal or trial of void
Secondary outcome [8] 459603 0
Total volume of CBI fluid used
Timepoint [8] 459603 0
From CBI commencement to final cessation
Secondary outcome [9] 459604 0
Interhospital transfer rate (satellite EDs other than Wollongong Hospital)
Timepoint [9] 459604 0
Assessed at any time from hospital admission to transfer following study drug administration excluding transfers to sub-acute hospital
Secondary outcome [10] 459605 0
Change in haemoglobin from admission to discharge
Timepoint [10] 459605 0
Admission and at discharge
Secondary outcome [11] 459606 0
Incidence of venous thromboembolism (deep vein thrombosis or pulmonary embolism). Deep vein thrombosis and pulmonary embolism are on the same spectrum of illness and will be assessed as a composite secondary outcome
Timepoint [11] 459606 0
Within 30 days of study drug administration
Secondary outcome [12] 459607 0
Rate of urological surgical intervention (e.g. cystoscopy, bladder washout, clot resection in theatre)
Timepoint [12] 459607 0
Within 30 days of study drug administration
Secondary outcome [13] 459655 0
Pain score
Timepoint [13] 459655 0
Just prior to infusion of study drug, again at end of 15 minute dwell time

Eligibility
Key inclusion criteria
1. Adults aged 18 years or over.

2. Clinically significant macroscopic haematuria requiring indwelling urinary catheter (IDC) placement and initiation of continuous bladder irrigation (CBI), based on at least one of:
- Clinical judgement and urine colour assessment; and/or
- Urinary retention secondary to suspected intravesical clot.

3. Willingness to give written or oral informed consent.

4. Willingness to participate in and comply with the study.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Haematuria in the context of suspected or proven upper or lower urinary tract trauma (excluding IDC-related superficial prostatic trauma with externally dislodged IDC requiring further management).

2. Suspected bladder perforation for any reason.

3. Documented tranexamic acid allergy.

4. Not suitable for IDC placement or unable to undergo manual bladder washout prior to study drug administration.

5. Patients with CBI already initiated.

6. Known or suspected pregnancy or breastfeeding.

7. Known or suspected organised intravesical clot unresponsive to manual irrigation.

8. Lacks capacity to provide informed consent at the time consent is sought.

9. Any other condition that, in the opinion of the treating clinician or principal investigator, would make participation unsafe or compromise study integrity.

10. Previously enrolled participants (no re-enrolment).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Centralised computer allocation via a secure web-based randomisation system (REDCap, OHMR server). The enrolling clinician logs into REDCap, enters the participant's study ID, and the system automatically allocates the participant to TXA or placebo. The study drug is then prepared by a designated unblinded clinician (Study Clinician 2) in a container identical in appearance to the comparator, labelled only with the participant's study ID.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Permuted block randomisation with variable block sizes (4 and 8), stratified by participating hospital, generated via REDCap computerised sequence generation prior to study commencement.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
Sample size: 80 participants (40 per arm) over 12 months. This is a feasibility-constrained sample size selected to provide informative precision around the treatment effect rather than to support a formal superiority claim.

Primary analysis: Cox proportional hazards model with treatment arm as the main effect Results reported as hazard ratio (HR) with 95% confidence interval, Kaplan-Meier curves, and numbers-at-risk.

Secondary outcomes: Analysed using intention-to-treat (ITT) and per-protocol approaches. Effect sizes with 95% CIs reported; p-values reported descriptively without multiplicity adjustment. P < 0.05 considered statistically significant. All analyses performed in R Studio.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 29316 0
Wollongong Hospital - Wollongong
Recruitment hospital [2] 29317 0
Shoalhaven Hospital - Nowra
Recruitment hospital [3] 29318 0
Shellharbour Hospital - Mount Warrigal
Recruitment hospital [4] 29319 0
Milton Ulladulla Hospital - Milton
Recruitment postcode(s) [1] 45634 0
2500 - Wollongong
Recruitment postcode(s) [2] 45635 0
2541 - Nowra
Recruitment postcode(s) [3] 45636 0
2528 - Mount Warrigal
Recruitment postcode(s) [4] 45637 0
2538 - Milton

Funding & Sponsors
Funding source category [1] 321433 0
Government body
Name [1] 321433 0
Illawarra Shoalhaven Local Health District
Country [1] 321433 0
Australia
Primary sponsor type
Government body
Name
Illawarra Shoalhaven Local Health District
Address
Country
Australia
Secondary sponsor category [1] 324238 0
None
Name [1] 324238 0
Address [1] 324238 0
Country [1] 324238 0
Other collaborator category [1] 283885 0
University
Name [1] 283885 0
University of Wollongong
Address [1] 283885 0
Country [1] 283885 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319973 0
St Vincent’s Hospital Human Research Ethics Committee
Ethics committee address [1] 319973 0
Ethics committee country [1] 319973 0
Australia
Date submitted for ethics approval [1] 319973 0
18/11/2025
Approval date [1] 319973 0
27/02/2026
Ethics approval number [1] 319973 0
2025_ETH02445

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149002 0
Dr Michael Nitzberg
Address 149002 0
Emergency Department, Wollongong Hospital, Loftus St, Wollongong NSW 2500
Country 149002 0
Australia
Phone 149002 0
+61 0477047668
Fax 149002 0
Email 149002 0
Contact person for public queries
Name 149003 0
Michael Nitzberg
Address 149003 0
Emergency Department, Wollongong Hospital, Loftus St, Wollongong NSW 2500
Country 149003 0
Australia
Phone 149003 0
+61 0477047668
Fax 149003 0
Email 149003 0
Contact person for scientific queries
Name 149004 0
Michael Nitzberg
Address 149004 0
Emergency Department, Wollongong Hospital, Loftus St, Wollongong NSW 2500
Country 149004 0
Australia
Phone 149004 0
+61 0477047668
Fax 149004 0
Email 149004 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
Yes: De-identified individual participant data may be considered for future secondary research use on reasonable request, subject to approval by the investigators and relevant ethics/governance bodies, and only where consistent with participant consent and applicable ethical requirements. Data will remain stored on the ISLHD OHMR REDCap server unless approval for approved data access or transfer is granted. Aggregate results will be published in peer-reviewed literature.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
TypeIs Peer Reviewed?DOICitations or Other DetailsAttachment
ProtocolNo TXA CBI Protocol Version 5 - Clean - 07.08.26.docx

Documents added automatically
No additional documents have been identified.